3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
6
Neoplasms
4
Myelodysplastic Syndromes
4
Carcinoma, Non-Small-Cell Lung
4
Urinary Bladder Neoplasms
2
Recurrence
2
Ovarian Neoplasms
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lung Neoplasms
2
Leukemia, Myelomonocytic, Chronic
2
Hematologic Neoplasms
2
Tumor Virus Infections
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Peritoneal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasm Metastasis
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Multiple Myeloma
1
Microsatellite Stable Colorectal Carcinoma
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Interventions
Fluorouracil
2
Docetaxel
2
thymoglobulin
1
temsirolimus
1
sargramostim
1
pirarubicin
1
pembrolizumab
1
pazopanib
1
fludarabine phosphate
1
fludarabine
1
cc-486
1
X-Rays
1
Whole-Body Irradiation
1
Trastuzumab
1
Tacrolimus
1
Surveys and Questionnaires
1
Rituximab
1
Radiotherapy
1
Proctectomy
1
Pemetrexed
1
Oxaliplatin
1
Mycophenolic Acid
1
Monatide (IMS 3015)
1
Metformin
1
Melphalan
1
Leucovorin
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Epirubicin
1
Drug Therapy
1
Diphenhydramine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Pathologic Complete Response
×
cc-486
×
Clear all
NCT01757535
2025-07-08
QUAZAR AML-001
Celgene
Phase 3
Completed
472 enrolled
24 charts
1 FDA